Your browser doesn't support javascript.
loading
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Cascone, Tina; Kar, Gozde; Spicer, Jonathan D; García-Campelo, Rosario; Weder, Walter; Daniel, Davey B; Spigel, David R; Hussein, Maen; Mazieres, Julien; Oliveira, Julio; Yau, Edwin H; Spira, Alexander I; Anagnostou, Valsamo; Mager, Raymond; Hamid, Oday; Cheng, Lin-Yang; Zheng, Ying; Blando, Jorge; Tan, Tze Heng; Surace, Michael; Rodriguez-Canales, Jaime; Gopalakrishnan, Vancheswaran; Sellman, Bret R; Grenga, Italia; Soo-Hoo, Yee; Kumar, Rakesh; McGrath, Lara; Forde, Patrick M.
Afiliação
  • Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kar G; AstraZeneca, Translational Medicine, Research and Early Development, Oncology Research and Development, Cambridge, United Kingdom.
  • Spicer JD; Department of Thoracic Surgery, McGill University, Montreal, Quebec, Canada.
  • García-Campelo R; Medical Oncology Unit, University Hospital A Coruña, A Coruña, Spain.
  • Weder W; Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland.
  • Daniel DB; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Spigel DR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Hussein M; Sarah Cannon Research Institute, Florida Cancer Specialists, Leesburg, Florida.
  • Mazieres J; Thoracic Oncology Department, Toulouse University Hospital, Toulouse, France.
  • Oliveira J; Medical Oncology Department, Portuguese Oncology Institute (IPO-PORTO), Porto, Portugal.
  • Yau EH; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Spira AI; Virginia Cancer Specialists, US Oncology Research, NEXT Oncology Virginia, Fairfax, Virginia.
  • Anagnostou V; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Mager R; AstraZeneca, Gaithersburg, Maryland.
  • Hamid O; AstraZeneca, Gaithersburg, Maryland.
  • Cheng LY; AstraZeneca, Gaithersburg, Maryland.
  • Zheng Y; AstraZeneca, Gaithersburg, Maryland.
  • Blando J; AstraZeneca, Gaithersburg, Maryland.
  • Tan TH; AstraZeneca, Munich, Germany.
  • Surace M; AstraZeneca, Gaithersburg, Maryland.
  • Rodriguez-Canales J; AstraZeneca, Gaithersburg, Maryland.
  • Gopalakrishnan V; AstraZeneca, Gaithersburg, Maryland.
  • Sellman BR; AstraZeneca, Gaithersburg, Maryland.
  • Grenga I; AstraZeneca, Waltham, Massachusetts.
  • Soo-Hoo Y; AstraZeneca, Gaithersburg, Maryland.
  • Kumar R; AstraZeneca, Gaithersburg, Maryland.
  • McGrath L; AstraZeneca, Waltham, Massachusetts.
  • Forde PM; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Cancer Discov ; 13(11): 2394-2411, 2023 11 01.
Article em En | MEDLINE | ID: mdl-37707791
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article